NCT06135935 is a NA clinical trial of No-added-sugar ice cream in Type 2 Diabetes, sponsored by Dasman Diabetes Institute.

Who is sponsoring NCT06135935?

NCT06135935 is sponsored by Dasman Diabetes Institute.

What drugs are being tested in NCT06135935?

Interventions in NCT06135935: No-added-sugar ice cream, Conventional products.

What condition does NCT06135935 study?

NCT06135935 studies Type 2 Diabetes.

Is NCT06135935 still recruiting?

NCT06135935 is currently status unknown. Last updated 18 November 2023.

Last reviewed 2023-11-18 · How we verify

NCT06135935

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Postprandial Glucose Response Using Mass-Market No-Added-Sugar Ice Cream

Status unknown NA Last updated 18 November 2023

What this trial tests

NA trial testing No-added-sugar ice cream in Type 2 Diabetes in 12 participants. Status unknown.

Timeline

12 November 2023

Primary endpoint
12 December 2023

30 January 2024

Quick facts

Lead sponsor	Dasman Diabetes Institute
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	screening
Enrollment	12
Start date	12 November 2023
Primary completion	12 December 2023
Estimated completion	30 January 2024
Sites	1 location across Kuwait

Drugs / interventions tested

No-added-sugar ice cream
Conventional products

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

Dasman Diabetes Institute

Who can join

18 and older, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

KDD is developing a new line of no-added-sugar products in line with its metabolic reengineering initiative and its metabolic matrix. The recipes fundamentally do not alter total saturated fat or protein levels and mainly offer the benefit of no added sugar and a significant reduction in net carbohydrates as well glycaemic index.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Reformulating ice cream to improve postprandial glucose response: an opportunity for industry to create shared value.
Al-Ozairi E, Mandani Y, Alfaleh G, Raj J, et al · · 2024 · PMID 39081682 · DOI 10.3389/fnut.2024.1349392

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other Dasman Diabetes Institute trials

Trials by the same sponsor.

NCT06922656 — Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Preven · Phase 4 · not yet recruiting
NCT06885736 — LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy · NA · recruiting
NCT07096908 — Tirzepatide Use in People With Obesity and Type 1 Diabetes · Phase 4 · not yet recruiting
NCT06984133 — Structured Education Program and Glycemic Control in Adolescents With Type 1 Diabetes · NA · recruiting
NCT07037810 — Compare Multiple Daily Injections With Carbohydrate Counting or With Simplified Qualitative Meal-Size Estimation in Type · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06135935 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dasman Diabetes Institute
Last refreshed: 18 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06135935.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing